Aclaris Therapeutics Azioni (NASDAQ: ACRS)

Ultime notizie per Aclaris Therapeutics (NASDAQ:ACRS) Azioni

Aclaris Therapeutics

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics Inc

<h3>Gainers</h3>
<ul>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) stock moved upwards by 26.4% to $3.26 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares increased by 19.1% to $3.74. The company's market cap stands at $267.1 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares rose 15.74% to $10.0. The market value of their outstanding shares is at $544.0 million. The company's, Q3 earnings came out 4 days ago. </li>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) shares rose 15.41% to $0.42. The company's market cap stands at $1.4 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares increased by 15.32% to $1.43. The company's market cap stands at $54.0 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) stock rose 14.36% to $1.1. The company's market cap stands at $26.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) stock fell 16.3% to $0.16 during Tuesday's pre-market session. The market value of their outstanding shares is at $17.8 million. </li>
<li>Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) stock fell 12.31% to $67.5. The market value of their outstanding shares is at $13.0 billion. </li>
<li>Cytek Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) stock declined by 10.78% to $5.38. The market value of their outstanding shares is at $693.0 million. </li>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares fell 10.42% to $8.26. The company's market cap stands at $5.6 billion. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares decreased by 9.8% to $0.26. The company's market cap stands at $1.4 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) stock decreased by 9.26% to $25.0. The company's market cap stands at $4.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ACRS

ALKS

ALMS

APLM

CTKB

FRES

GCTK

GRFS

HCWB

INCY

SNOA

TFFP

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

On Monday, Aclaris Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) entered into an exclusive license agreement with Biosion Inc for worldwide rights (excluding Greater China) to BSI-045B and BSI-502, a preclinical-stage, novel bispecific antibody directed against <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42034751/aclaris-therapeutics-announces-exclusive-global-license-agreement-with-biosion-inc-adding-potentia" rel="noreferrer noopener">both TSLP and IL4R</a>.
In a completed Phase 2a, single-arm, proof-of-concept trial in the United States in 22 patients with moderate to severe atopic dermatitis, BSI-045B was observed to have a pharmacodynamic, safety, and efficacy profile.
BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion&#8217;s regional partner, Chia Tai Tianqing Pharmaceutical Group, Co., Ltd. (CTTQ), targeting severe asthma and chronic rhinosinusitis with nasal polyps, accelerating the potential to show proof-of-concept across additional indications.
Under the terms of the agreement, Biosion shall receive over&nbsp;$40 million&nbsp;cash payment as an upfront license fee and reimbursement for certain development costs &amp; drug product materials.
Biosion shall also receive 19.9% shares of Aclaris Therapeutics.
Additional regulatory and sales milestone payments exceed&nbsp;$900 million, with tiered low-to-mid single-digit royalty payments based on a percentage of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42036056/biosion-announces-exclusive-global-license-agreement-with-aclaris-therapeutics-on-two-potential-fi" rel="noreferrer noopener">annual net sales</a>.
Leerink Partners upgraded Aclaris from Market Perform to Outperform, with a price target of $7, <a target="_blank" href="https://www.benzinga.com/quote/ACRS/analyst-ratings" rel="noreferrer noopener">up from $2</a>.
The analyst writes, &#8220;Following completion of their strategic review, we expect investor focus to shift to ACRS&#8217; newly strengthened immunology-focused pipeline.&#8221;
Leerink writes that these updates mark a fresh start for Aclaris Therapeutics, with a clear strategic direction and promising catalysts in the next 6-12 months. This progress could reduce risks for BSI-045B and significantly enhance its value.
The analyst has updated the model to include BSI-045 B&#8217;s potential in atopic dermatitis (AD), estimating around $1.3 billion in revenue by 2035 with a 35% probability of success. The analyst also anticipates multiple Phase 2 trial results from China in asthma and chronic rhinosinusitis with nasal polyps, which could provide more insight into BSI-045 B&#8217;s potential.
Additionally, Leerink expects further progress in de-risking the company&#8217;s pipeline in the first half of next year.
BTIG upgrades Aclaris Therapeutics from Neutral to Buy and announces a $8 price target.
Price Action: ACRS stock is up 55.60% at $4.88 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42063475/interactive-strength-shares-jumps-premarket-as-saudi-fitness-chain-adopts-clmbr-machines" target="_blank" rel="noreferrer noopener">Interactive Strength Shares Jump As Saudi Fitness Chain Adopts CLMBR Machines: Details</a></li>
</ul>

Analyst Color

Biotech

News

Upgrades

Health Care

Price Target

Contracts

Analyst Ratings

Trading Ideas

General

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/607ebdb217ff280001130e2a/julian-harrison">BTIG analyst Julian Harrison</a> upgraded the rating for Aclaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and announced a price target of $8. Aclaris Therapeutics shares closed at $3.14 on Monday. <a href="https://www.benzinga.com/quote/ACRS/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/650428998345120001a2f3ec/wesley-brooks">HSBC analyst Wesley Brooks</a> upgraded the rating for QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) from Reduce to Hold and announced a price target of $5.3. QuantumScape shares closed at $4.73 on Monday. <a href="https://www.benzinga.com/quote/QS/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5809e400846faa000106ad3a/cory-kasimov">Evercore ISI Group analyst Cory Kasimov</a> upgraded the rating for BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) from In-Line to Outperform and boosted the price target from $110 to $125. BioNTech shares closed at $101.87 on Monday. <a href="https://www.benzinga.com/quote/BNTX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity analyst Matthew Lee upgraded Bank of Nova Scotia (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BNS#TSX">BNS</a>) from Hold to Buy and raised the price target from C$71 to C$84. <a href="https://www.benzinga.com/quote/BNS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies analyst Roger Song upgraded the rating for Aclaris Therapeutics, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Hold to Buy and raised the price target from $2 to $7. Aclaris Therapeutics shares closed at $3.14 on Monday. <a href="https://www.benzinga.com/quote/acrs/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying BNTX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="559" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19073934/image-195-1024x559.png" alt="" class="wp-image-654905" style="width:678px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19073934/image-195-1024x559.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19073934/image-195-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19073934/image-195-768x419.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19073934/image-195.png 1205w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42035732/jim-cramer-super-group-basic-materials-stock-is-very-hard-to-own-here">Jim Cramer: Super Group Finally &#8216;Broke Out,&#8217; This Basic Materials Stock Is &#8216;Very Hard To Own Here&#8217;</a></li>
</ul>

Pre-Market Outlook

Markets

ACHR

ACNB

BNTX

TSX:BNS

This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Leerink Partners analyst Thomas Smith upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Market Perform to Outperform and raises the price target from $2 to $7.

Leerink Partners Upgrades Aclaris Therapeutics to Outperform, Raises Price Target to $7

Jefferies analyst Roger Song upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Hold to Buy and raises the price target from $2 to $7.

Jefferies Upgrades Aclaris Therapeutics to Buy, Raises Price Target to $7

WIIM

Aclaris Therapeutics shares are trading higher after Piper Sandler upgraded the stock from Neutral to Overweight and raised its price target from $3 to $13. Also, BTIG upgraded the stock from Neutral to Buy and announced a price target of $8.

BTIG analyst Julian Harrison upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and announces $8 price target.

BTIG Upgrades Aclaris Therapeutics to Buy, Announces $8 Price Target

Piper Sandler analyst Christopher Raymond upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Overweight and raises the price target from $3 to $13.

Piper Sandler Upgrades Aclaris Therapeutics to Overweight, Raises Price Target to $13

Aclaris Therapeutics Shares Spike Higher; Piper Sandler Upgrades Stock To Overweight With $13 Target Following Biosion Deal; Highlights Pipeline For Atopic Dermatitis And I&I Market, Catalysts Expected In 2025 Trials

Aclaris Therapeutics shares are trading higher after the company announced it entered into an exclusive license agreement with Biosion for worldwide rights to BSI-045B. The company announced an $80 million private placement.

Aclaris Therapeutics Secures $80M Through Private Placement Of 35.56M Shares At $2.25 Per Share; Funds To Support Pipeline Development And General Corporate Purposes

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion For Worldwide Rights (Excluding Greater China) To BSI-045B

Earnings

Guidance

Aclaris Had Aggregate Cash, Cash Equivalents And Marketable Securities Of $173.4M As Of September 30, Which Is Expected To Provide Cash Runway Into 2028

Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $0.02 by 650 percent. This is a 73.17 percent increase over losses of $(0.41) per share from the same period last year. The company reported quarterly sales of $4.35 million which missed the analyst consensus estimate of $7.12 million by 38.95 percent. This is a 53.18 percent decrease over sales of $9.28 million the same period last year.

Aclaris Therapeutics Q3 2024 GAAP EPS $(0.11) Misses $0.02 Estimate, Sales $4.35M Miss $7.12M Estimate

<h3>Gainers</h3>
<ul>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) stock increased by 128.3% to $12.1 during Monday's pre-market session. The market value of their outstanding shares is at $8.8 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock moved upwards by 93.43% to $1.12. The market value of their outstanding shares is at $6.3 million. </li>
<li>Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) shares rose 30.47% to $6.38. The market value of their outstanding shares is at $391.5 million. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) stock increased by 21.06% to $5.69. The company's market cap stands at $592.7 million. </li>
<li>PROCEPT BioRobotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>) stock moved upwards by 14.87% to $79.0. The company's market cap stands at $4.1 billion. The company's, Q3 earnings came out today. </li>
<li>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) stock rose 14.26% to $16.5. The company's market cap stands at $17.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Koninklijke Philips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) stock decreased by 16.9% to $26.31 during Monday's pre-market session. The market value of their outstanding shares is at $24.5 billion. The company's, Q3 earnings came out today. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) stock decreased by 12.88% to $14.75. The company's market cap stands at $51.9 million. </li>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) shares declined by 10.84% to $0.36. The market value of their outstanding shares is at $19.8 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) stock declined by 8.29% to $1.55. The company's market cap stands at $110.5 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares decreased by 7.94% to $0.37. The company's market cap stands at $26.4 million. </li>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) shares decreased by 7.92% to $0.44. The company's market cap stands at $14.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AVTX

EVOK

GLUE

HCTI

MNDR

MNPR

MRNS

PRCT

RVNC

XAIR

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 93.4% to $1.12 during Monday's pre-market session. The market value of their outstanding shares is at $6.3 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares rose 71.53% to $9.09. The market value of their outstanding shares is at $6.6 million. </li>
<li>Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) shares moved upwards by 32.1% to $6.46. The market value of their outstanding shares is at $396.4 million. </li>
<li>Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) shares moved upwards by 22.27% to $1.18. The company's market cap stands at $18.9 million. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) stock rose 21.04% to $5.69. The company's market cap stands at $592.6 million. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) stock moved upwards by 15.5% to $1.49. The market value of their outstanding shares is at $22.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Koninklijke Philips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) stock declined by 17.0% to $26.29 during Monday's pre-market session. The market value of their outstanding shares is at $24.5 billion. As per the news, the Q3 earnings report came out today. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) stock fell 12.88% to $14.75. The company's market cap stands at $51.9 million. </li>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) stock decreased by 10.84% to $0.36. The market value of their outstanding shares is at $19.8 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock declined by 9.84% to $0.32. The company's market cap stands at $4.7 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares declined by 8.88% to $1.54. The market value of their outstanding shares is at $109.8 million. </li>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) stock decreased by 8.06% to $0.44. The market value of their outstanding shares is at $14.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ENSC

MIRA

<h3>Gainers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares moved upwards by 62.3% to $0.94 during Friday's after-market session. The company's market cap stands at $5.3 million. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) shares rose 23.25% to $1.59. The market value of their outstanding shares is at $23.5 million. </li>
<li>MEI Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEIP#NASDAQ">MEIP</a>) shares rose 22.54% to $3.37. The market value of their outstanding shares is at $22.4 million. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) shares moved upwards by 16.05% to $5.35. The market value of their outstanding shares is at $224.6 million. </li>
<li>P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) stock increased by 15.24% to $0.47. The market value of their outstanding shares is at $75.7 million. </li>
<li>OKYO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) stock rose 9.52% to $1.38. The market value of their outstanding shares is at $46.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares declined by 9.5% to $1.53 during Friday's after-market session. The market value of their outstanding shares is at $109.1 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) stock declined by 6.95% to $0.37. The company's market cap stands at $26.7 million. </li>
<li>Qualigen Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) stock decreased by 6.92% to $0.11. The company's market cap stands at $3.0 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock fell 6.92% to $1.73. The market value of their outstanding shares is at $3.2 million. </li>
<li>Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) stock fell 6.69% to $5.86. The market value of their outstanding shares is at $400.7 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock fell 6.44% to $0.46. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CMPS

HSDT

HURA

MEIP

NUWE

OKYO

PIII

Qualigen Therapeutics, Inc. - Common Stock

QLGN

12 Health Care Stocks Moving In Friday's After-Market Session

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) with a Neutral.

Reiteration

HC Wainwright & Co. Reiterates Neutral on Aclaris Therapeutics

The Phase 2a trial is an open-label study to investigate the safety, tolerability, pharmacokinetics, efficacy, and pharmacodynamics of ATI-2138 administered over 12 weeks in patients with moderate to severe atopic dermatitis. Aclaris&#39; planned enrollment for this trial is approximately 15 subjects, and the trial will be conducted in the United States. The primary endpoints are safety-related parameters. Secondary endpoints include Eczema Area and Severity Index (EASI) response measures, including EASI-50, EASI-75, and EASI-90, Validated Investigator Global Assessment (vIGA) response, body surface area (BSA)&nbsp;response and other pertinent efficacy related measures. Aclaris expects topline data from this trial in the first half of 2025

Aclaris Therapeutics Doses First Patient In Phase 2a Trial Of ATI-2138 For Moderate To Severe Atopic Dermatitis

Jefferies upgraded Aclaris Therapeutics (ACRS) to Buy from Hold with a price target of $7, up from $2. BSI-045B is the first anti-TSLP showing clin...

Aclaris Therapeutics upgraded to Buy from Hold at Jefferies

Leerink upgraded Aclaris Therapeutics (ACRS) to Outperform from Market Perform with a price target of $7, up from $2, representing over 120% upside...

Aclaris Therapeutics upgraded to Outperform from Market Perform at Leerink

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Workday initiated, Kraft Heinz downgraded: Wall Street's top analyst calls

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Walmart (WMT) provided a "beat and rai...

Walmart higher, Lowe's lower after earnings: Morning Buzz

Geopolitical tensions drive market moves as we analyze top picks.

War, Gold, And Opportunity: Uncovering Today's Market Moves

Aclaris stock soars for second day on licensing deal, analyst upgrades

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Cantor Fitzgerald analyst Louise Chen upgraded Aclaris Therapeutics (ACRS) to Overweight from Neutral with no price target after the company earlie...

Aclaris upgraded at Cantor after deal adds two 'potential blockbusters'

Cantor Fitzgerald upgraded Aclaris Therapeutics (ACRS) to Overweight from Neutral. Published first on TheFly – the ultimate source for real-time, m...

Aclaris Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald

Aclaris upgraded to overweight by Cantor on in-licensing deal

AAPL

ADSK

AMZN

APLS

ARKK

ASAN

BERY

BLNK

CART

CHPT

FATE

GOOG

GOOGL

IIIV

INTC

INTU

ISRG

JNPR

JOBY

MNDY

MRNA

MSFT

OKTA

RCAT

RGNX

SABR

SMCI

SNEJF

SONY

UBER

VEEV

WDAY

XCUR

Press Releases

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Aclaris Therapeutics Announces $80 Million Private Placement

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

This Healthcare Stock is Soaring Following Exclusive License Agreement Announcement

Peraso Inc. (NASDAQ: PRSO): Intro-Act Targets $3.30 Per Share After Positive Q3 Performance see more stocks inside….

Comments

Aclaris Therapeutics

Notizie

Ultime notizie per Aclaris Therapeutics (NASDAQ:ACRS) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO